2 -Adrenoceptor-mediated vasoconstriction requires a tyrosine kinase

By Jinsi A.   Deth R.C.  

European Journal of Pharmacology, Vol. 277, Iss. 1, 1995-04 ,pp. : 29-34

Elsevier

Access to resources Recommend Favorite

A-315456: a selective 1D -adrenoceptor antagonist with minimal dopamine D 2 and 5-HT 1A receptor affinity

By Buckner S.A.   Milicic I.   Daza A.   Lynch J.J.   Kolasa T.   Nakane M.   Sullivan J.P.   Brioni J.D.  

European Journal of Pharmacology, Vol. 433, Iss. 1, 2001-12 ,pp. : 123-127

Elsevier

Access to resources Recommend Favorite

SDZ NVI 985, an 1A -adrenoceptor agonist with 5-HT 2A receptor antagonist properties

By Lachnit W.G.   Ford A.P.D.W.   Clarke D.E.  

European Journal of Pharmacology, Vol. 297, Iss. 1, 1996-02 ,pp. : 83-86

Elsevier

Access to resources Recommend Favorite

The corticosterone-enhancing effects of the 5-HT 1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT 1A receptor

By Groenink L.   Van der Gugten J.   Mos J.   Maes R.A.A.   Oliver B.  

European Journal of Pharmacology, Vol. 272, Iss. 2, 1995-01 ,pp. : 177-183

Elsevier

Access to resources Recommend Favorite

Intracellular alkalinization augments 1 -adrenoceptor-mediated vasoconstriction by promotion of Ca 2+ entry through the non-L-type Ca 2+ channels

By Wakabayashi I.   Masui H.   Groschner K.  

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 251-259

Elsevier

Access to resources Recommend Favorite